🇺🇸 FDA

Intelligence · Patent portfolio

IONIS PHARMACEUTICALS Patents

Full USPTO pharma patent portfolio for IONIS PHARMACEUTICALS — grant dates, expiration, and drug cross-links.

Patents
222
Expiring ≤24m
0

Quick answer

IONIS PHARMACEUTICALS has 222 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 5

  1. US 11661455

    Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11634711

    Methods and compositions for modulating apolipoprotein (a) expression

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11633483

    Modulators of PCSK9 expression

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11629348

    Linkage modified oligomeric compounds and uses thereof

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11613752

    Compositions and methods for modulating PKK expression

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11583548

    Compounds and methods for reducing ATXN3 expression

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11566072

    CD8 binding agents

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11547718

    Modulators of FOXP3 expression

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11542504

    Compounds and methods for modulating ATXN1

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11535849

    Modulation of transthyretin expression

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11530410

    Methods for treating hypercholesterolemia

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11530411

    Methods for reducing LRRK2 expression

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11525136

    Modulators of APOL1 expression

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11498966

    PD-1 and PD-L1 binding agents

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11492617

    Compositions and methods for modulation of protein aggregation

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11447521

    Compounds and methods for modulating angiotensinogen expression

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11440943

    Therapeutic interferon alpha 1 proteins

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11421231

    Modulation of Huntington expression

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11414657

    Modified CRISPR RNA and modified single CRISPR RNA and uses thereof

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11400161

    Method of conjugating oligomeric compounds

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11384154

    Targeted chimeric proteins and uses thereof

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11376273

    Modulation of factor 11 expression

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11365416

    Modulators of EZH2 expression

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11339393

    Compositions for modulating C9ORF72 expression

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11332746

    Compounds and methods for reducing LRRK2 expression

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11319536

    Modulating apolipoprotein (a) expression

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11312964

    Compositions and methods for modulating growth hormone receptor expression

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11312962

    Modulators of diacyglycerol acyltransferase 2 (DGAT2)

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11299737

    Compounds and methods for modulating SMN2

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11299736

    Conjugated antisense compounds and their use

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11293025

    Compositions and methods for modulating Ataxin 3 expression

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11241451

    Modulators of IRF4 expression

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11236339

    Modulation of GYS1 expression

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11236335

    Selective antisense compounds and uses thereof

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11236166

    CD8 binding agents

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11236141

    Targeted mutant interferon-beta and uses thereof

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11230712

    Compounds and methods for reducing SNCA expression

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11225664

    Modulation of angiopoietin-like 3 expression

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11214803

    Modulators of YAP1 expression

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11208650

    Modulators of IRF5 expression

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11197884

    Modulation of the notch signaling pathway for treatment of respiratory disorders

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11193128

    Compositions for modulating expression of C9ORF72 antisense transcript

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11155815

    Compositions and methods for modulating Tau expression

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11136577

    Methods and compositions for inhibiting PMP22 expression

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11129844

    Compositions and methods for modulating MECP2 expression

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11116843

    Conjugated antisense compounds and their use

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11118183

    Modulation of angiopoietin-like 3 expression

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11111494

    Compositions for modulating Ataxin 2 expression

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does IONIS PHARMACEUTICALS have?

222 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do IONIS PHARMACEUTICALS patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.